Problems and prospects in gene therapy for hemophilia

Current Opinion in Hematology

Volumn 5, Issue 5, 1998, Pages 321-326

  Herzog, Roland W ^a   High, Katherine A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLONING VECTOR; DOG; GENE THERAPY; GENE TRANSFER; HEMOPHILIA; HUMAN; LIVER; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW;

EID: 0031698579     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199809000-00003     Document Type: Review

References (49)

1. High KA: Factor IX: Molecular structure, epitopes, and mutations associated with inhibitor formation. In Advances in Experimental Medicine and Biology, edn 1. Edited by Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. New York: 1995; 79-86.
2. Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ, et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995, 1:1148-1154.
3. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al.: T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270:475-480.
4. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, et al.: In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993, 262:117-119.
5. Okuyama T, Huber RM, Bowling W, Pearline R, Kennedy SC, Flye MW, Ponder KP: Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha-1-antitrypsin promoter dramatically increases expression of human alpha 1 -antitrypsin in vivo. Hum Gene Ther 1996, 7:637-645.
6. Le M, Okuyama T, Cai SR, Kennedy SC, Bowling WM, Flye MW, Ponder • KP: Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood 1997, 89:1254-1259. In earlier studies, retroviral gene transfer was too inefficient for most clinical applications. This study demonstrated high levels of clotting factor expression using a liver-specific promoter to drive transgene expression.
7. Bosch A, McCray PB, Chang SMw, Ulich TR, Simnet WS, Jolly DJ, Davidson BL: Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. J Clin Invest 1996, 98:2683-2687.
8. Bowling WM, Kennedy SC, Cai SR, Duncan Jr, Gao C, Flye MW, Ponder KP: Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum Gene Ther 1996, 7:2113-2121.
9. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M: Sustained • expression of therapeutic levels of human factor VIII in mice. Blood 1996, 87:4671-4677. Using an adenoviral vector, these investigators were able to achieve sustained high levels of human factor VIII in vivo.
10. Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD: Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996, 88:3846-3853.
11. Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M: In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995, 6:185-193.
12. Yang Y, Joos KU, Su Q, Ertl HCJ, Wilson JM: Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996, 3:137-144.
13. Connelly S, Gardner JM, McClelland, Kaleko M: High level tissue-specific expression of functional human FVIII in mice. Hum Gene Ther 1996c, 7:183-195.
14. Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L, et al: Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998, 91:3273-3281.
15. Barr D, Tubb J, Ferguson D, Scaria A, Leiber A, Wilson C, et al.: Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 1995, 2:151-155.
16. Michou A, Santoro L, Christ M, Julliard V, Pavirani A, Mehtali M: Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 1997, 4:473-482.
17. Smith TAG, White BD, Gardner JM, Kaleko M, McClelland A: Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996, 3:496-502.
18. Kay MA, Meuse L, Gown AM, Linsley P, Hollenbaugh D, Aruffo A, et al.: Transient immunomodulation with anti-CD40 ligand antibody and CTLA4lg enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A 1997, 94:4686-4691.
19. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH: Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther 1997, 4:393-400.
20. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps L: Construction of adenovirus vectors through cre-lox recombination. J Virol 1997, 71:1842-1849.
21. Nelson JE, Kay MA: Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J Virol 1997, 71:8902-8907.
22. Lieber A, He CY, Kay MA: Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotech 1997, 15:1383-1387.
23. Xiao X, Li J, Samulski RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996, 70:8098-8108.
24. Fisher KJ, Jooss K, Alston J, Yang Y, Ehlen-Haecker S, High K, et al.: Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997, 3:306-312.
25. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B, Cohen LK, Danos O: Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997, 8:1891-1900.
26. Yao S-N, Smith KJ, Kurachi K: Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther 1994, 1:99-107.
27. Herzog RW, Hagstrom JN, Kung Z-H, Tai SJ, Wilson JM, Fisher KJ, High •• KA: Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997, 94:5804-5809. This study was the first to demonstrate therapeutic levels of human factor IX in mice from an AAV vector and may represent the most promising vector system for early human trials.
28. Monahan PE, Samulski PJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS: Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998, 5:40-49.
29. Herzog RW, Hagstrom JN, Hung S-L, Yang EY, Couto LB, Kurtzman GJ, et al.: Absence of antibodies against factor IX following IM injection of an AAV vector encoding a species-specific transgene. Blood 1997, 90:1957.
30. Cheung W-F, Born Jvd, Kühn K, Kjelléen L, Hudson BG, Stafford DW: Identification of the endothelial binding site for factor IX. Proc Natl Acad Sci U S A 1996, 93:11068-11073.
31. Yang CG, Xiao X, Ansardi DC, Epstein ND, Frey MR, Matera AG, Samulski RJ: Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol 1997, 71:9231-9247.
32. Ponnazhagan S, Mukherjee P, Yoder MC, Wang X-S, Zhou SZ, Kaplan J, Wadsworth S, Srivastava A: Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997, 190:203-210.
33. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD: Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 1997, 94:1426-1431.
34. Fisher KJ, Gao G-P, Weitzman MD, DeMatteo R, Burda JF, Wilson JF: Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996, 70:520-532.
35. Nakai H, Herzog R, Hagstrom JN, Kung J, Walter J, Tai S, et al.: AAV-medi•ated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998, 91:4600-4607. In this study high levels of expression were achieved from hepatocytes using an AAV vector containing a strong eukaryotic promoter, but not within a vector containing the cytomegalovirus promoter.
36. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, et al.: •• Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997, 16:270-276. This study was the first to demonstrate therapeutic levels of liver-derived factor IX expression from an AAV vector.
37. Löser P, Jennings SG, Strauss M, Sandig V: Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkB. J Virol 1998, 72:180-190.
38. Hurwitz DR, Kirchgesser M, Merrill W, Galanopoulos T, McGrath CA, Emami S, et al.: Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 1997, 8:137-156.
39. Wang J-M, Zheng H, Blaivas M, Kurachi K: Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels. Blood 1997, 90:1075-1082.
40. Kren BT, Bandyopadhayay P, Steer CJ: In vivo site-directed mutagenesis • of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med 1998, 4:285-290. Demonstrates a potential new gene therapy strategy for correcting point mutations in factor IX-deficient patients.
41. Lin H-F, Maeda N, Smithies O, Straight DL, Stafford DW: A coagulation • factor IX-deficient mouse model for human hemophilia B. Blood 1997, 90:3962-3966. This group was the first to genetically engineer a small animal model for factor IX deficiency.
42. Detloff PJ, Lewis J, John SW, Shehee WR, Langenbach R, Maeda N, Smithies O: Deletion and replacement of the mouse adult beta-globin genes by a "plug and socket" repeated targeting strategy. Mol Cell Biol 1994, 14:6936-6943.
43. Kung J, Hagstrom J, Cass D, Tai S, Lin HF, Stafford DW, High KA: Human • factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998, 91:784-790. Provides a detailed characterization of the assays required to study gene therapy in a mouse model of hemophilia B.
44. Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee K-F, Verma IM: A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 1997, 94:11563-11566.
45. Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S, Giles A, • Lillicrap D: The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost 1998, 79:317-322. The information provided in this study can be used to characterize mutations underlying hemophilia A in canine models of the disease.
46. Evans JP, Watzke HH, Ware JL, Stafford DW, High KA: Molecular cloning of a cDNA encoding canine factor IX. Blood 1989, 74:207-212.
47. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA: Canine hemo•philia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A 1989, 86:10095-1009. Describes a large animal model of hemophilia B caused by a missense mutation in the factor IX gene.
48. Mauser AE, Whitlark J, Whitney KM, Lothrop CD: A deletion mutation • causes hemophilia B in Lhasa Apso dogs. Blood 1996, 88:3451-3455. Describes a large animal model of hemophilia B caused by a deletion in the factor IX gene.
49. Brooks MB, Gu W, Ray K: Complete deletion of factor IX gene and inhibition of factor IX activity in a Labrador retriever with hemophilia B. JAMA 1997, 211:1418-21.